Pharmaceuticals
Pharma - Formulators
from 330 today
Marksans Pharma remains well-positioned to capitalise on structural growth opportunities across global regulated healthcare markets, supported by strategic European acquisitions and front-end market entries. We recommend a BUY on the stock with a target price of Rs 362/share, implying an upside of 10% from the CMP.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
